Intratumoral CRH modulates immuno-escape of ovarian cancer cells through FasL regulation

British Journal of Cancer

Volumn 97, Issue 5, 2007, Pages 637-645

  Minas, V ^a   Rolaki, A ^a   Kalantaridou, S N ^b   Sidiropoulos, J ^b   Mitrou, S ^b   Petsas, G ^a   Jeschke, U ^c   Paraskevaidis, E A ^b   Fountzilas, G ^d   Chrousos, G P ^e   Pavlidis, N ^b   Makrigiannakis, A ^a  

^a UNIVERSITY OF CRETE   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

^c UNIVERSITY OF MUNICH   (Germany)

^d ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^e UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Apoptosis; CRH; Fas ligand; Immune privilege; Ovarian cancer

Indexed keywords

CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; CORTICOTROPIN RELEASING FACTOR RECEPTOR 2; FAS LIGAND; MESSENGER RNA;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE ACTIVATION; OVARY CANCER; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM;

APOPTOSIS; BLOTTING, WESTERN; CASPASES; CELL LINE, TUMOR; CELL PROLIFERATION; CORTICOTROPIN-RELEASING HORMONE; FAS LIGAND PROTEIN; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOCYTES; NEOPLASM STAGING; OVARIAN NEOPLASMS; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; UP-REGULATION;

EID: 34548303692     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603918     Document Type: Article

References (45)

1. Abrahams VM, Straszewski SL, Kamsteeg M, Hanczaruk B, Schwartz PE, Rutherford TJ, Mor G (2003) Epithelial ovarian cancer cells secrete functional Fas ligand. Cancer Res 63: 5573-5581
2. Arbiser JL, Karalis K, Viswanathan A, Koike C, Anand-Apte B, Flynn E, Zetter B, Majzoub JA (1999) Corticotropin-releasing hormone stimulates angiogenesis and epithelial tumor growth in the skin. J Invest Dermatol 113: 838-842
3. Bale TL, Vale WW (2004) CRF and CRF receptors: role in stress responsivity and other behaviors. Annu Rev Pharmacol Toxicol 44: 525-557
4. Bellgrau D, Gold D, Selawry H, Moore J, Franzusoff A, Duke RC (1995) A role for CD95 ligand in preventing graft rejection. Nature 377: 630-632
5. Boorse GC, Denver RJ (2006) Widespread tissue distribution and diverse functions of corticotropin-releasing factor and related peptides. Gen Comp Endocrinol 146: 9-18
6. Bossi G, Griffiths GM (1999) Degranulation plays an essential part in regulating cell surface expression of Fas ligand in T cells and natural killer cells. Nat Med 5: 90-96
7. Calogero AE, Burrello N, Negri-Cesi P, Papale L, Palumbo MA, Cianci A, Sanfilippo S, D'Agata R (1996) Effects of corticotropin-releasing hormone on ovarian estrogen production in vitro. Endocrinology 137: 4161-4166
8. Ciocca DR, Puy LA, Fasoli LC, Tello O, Aznar JC, Gago FE, Papa SI, Sonego R (1990) Corticotropin-releasing hormone, luteinizing hormone-releasing hormone, growth hormone-releasing hormone, and somatostatin-like immunoreactivities in biopsies from breast cancer patients. Breast Cancer Res Treat 15: 175-184
9. Dermitzaki E, Tsatsanis C, Gravanis A, Margioris AN (2002) Corticotropin-releasing hormone induces Fas ligand production and apoptosis in PC12 cells via activation of p38 mitogen-activated protein kinase. J Biol Chem 277: 12280-12287
10. Erden HF, Zwain IH, Asakura H, Yen SS (1998) Corticotropin-releasing factor inhibits luteinizing hormone-stimulated P450c17 gene expression and androgen production by isolated thecal cells of human ovarian follicles. J Clin Endocrinol Metab 83: 448-452
11. Funasaka Y, Sato H, Chakraborty AK, Ohashi A, Chrousos GP, Ichihashi M (1999) Expression of proopiomelanocortin, corticotropin-releasing hormone (CRH), and CRH receptor in melanoma cells, nevus cells, and normal human melanocytes. J Investig Dermatol Symp Proc 4: 105-109
12. Ghizzoni L, Mastorakos G, Vottero A, Barreca A, Furlini M, Cesarone A, Ferrari B, Chrousos GP, Bernasconi S (1997) Corticotropin-releasing hormone (CRH) inhibits steroid biosynthesis by cultured human granulosa-lutein cells in a CRH and interleukin-1 receptor-mediated fashion. Endocrinology 138: 4806-4811
13. Grammatopoulos DK, Chrousos GP (2002) Functional characteristics of CRH receptors and potential clinical applications of CRH-receptor antagonists. Trends Endocrinol Metab 13: 436-444
14. Graziani G, Tentori L, Muzi A, Vergati M, Tringali G, Pozzoli G, Navarra P (2007) Evidence that corticotropin-releasing hormone inhibits cell growth of human breast cancer cells via the activation of CRH-R1 receptor subtype. Mol Cell Endocrinol 264: 44-49
15. Graziani G, Tentori L, Portarena I, Barbarino M, Tringali G, Pozzoli G, Navarra P (2002) CRH inhibits cell growth of human endometrial adenocarcinoma cells via CRH-receptor 1-mediated activation of cAMP-PKA pathway. Endocrinology 143: 807-813
16. Griffith TS, Yu X, Herndon JM, Green DR, Ferguson TA (1996) CD95-induced apoptosis of lymphocytes in an immune privileged site induces immunological tolerance. Immunity 5: 7-16
17. Ito Y, Monden M, Takeda T, Eguchi H, Umeshita K, Nagano H, Nakamori S, Dono K, Sakon M, Nakamura M, Tsujimoto M, Nakahara M, Nakao K, Yokosaki Y, Matsuura N (2000) The status of Fas and Fas ligand expression can predict recurrence of hepatocellular carcinoma. Br J Cancer 82: 1211-1217
18. Kim YS, Kim KH, Choi JA, Lee JH, Kim HK, Won NH, Kim I (2000) Fas (APO-1/CD95) ligand and Fas expression in renal cell carcinomas: correlation with the prognostic factors. Arch Pathol Lab Med 124: 687-693
19. Makrigiannakis A, Zoumakis E, Kalantaridou S, Coutifaris C, Margioris AN, Coukos G, Rice KC, Gravanis A, Chrousos GP (2001) Corticotropin-releasing hormone promotes blastocyst implantation and early maternal tolerance. Nat Immunol 2: 1018-1024
20. Mastorakos G, Scopa CD, Vryonidou A, Friedman TC, Kattis D, Phenekos C, Merino MJ, Chrousos GP (1994) Presence of immunoreactive corticotropin-releasing hormone in normal and polycystic human ovaries. J Clin Endocrinol Metab 79: 1191-1197
21. Mastorakos G, Webster EL, Friedman TC, Chrousos GP (1993) Immunoreactive corticotropin-releasing hormone and its binding sites in the rat ovary. J Clin Invest 92: 961-968
22. Meng Y, Graves L, Do TV, So J, Fishman DA (2004) Upregulation of FasL by LPA on ovarian cancer cell surface leads to apoptosis of activated lymphocytes. Gynecol Oncol 95: 488-495
23. Mor G, Kohen F, Garcia-Velasco J, Nilsen J, Brown W, Song J, Naftolin F (2000) Regulation of fas ligand expression in breast cancer cells by estrogen: functional differences between estradiol and tamoxifen. J Steroid Biochem Mol Biol 73: 185-194
24. Mottolese M, Buglioni S, Bracalenti C, Cardarelli MA, Ciabocco L, Giannarelli D, Botti C, Natali PG, Concetti A, Venanzi FM (2000) Prognostic relevance of altered Fas (CD95)-system in human breast cancer. Int J Cancer 89: 127-132
25. Munakata S, Enomoto T, Tsujimoto M, Otsuki Y, Miwa H, Kanno H, Aozasa K (2000) Expressions of Fas ligand and other apoptosis-related genes and their prognostic significance in epithelial ovarian neoplasms. Br J Cancer 82: 1446-1452
26. Muramatsu Y, Sugino N, Suzuki T, Totsune K, Takahashi K, Tashiro A, Hongo M, Oki Y, Sasano H (2001) Urocortin and corticotropin-releasing factor receptor expression in normal cycling human ovaries. J Clin Endocrinol Metab 86: 1362-1369
27. Niehans GA, Brunner T, Frizelle SP, Liston JC, Salerno CT, Knapp DJ, Green DR, Kratzke RA (1997) Human lung carcinomas express Fas ligand. Cancer Res 57: 1007-1012
28. O'Connell J, Bennett MW, O'ullivan GC, Collins JK, Shanahan F (1999) The Fas counterattack: cancer as a site of immune privilege. Immunol Today 20: 46-52
29. O'Connell J, Houston A, Bennett MW, O'ullivan GC, Shanahan F (2001) Immune privilege or inflammation? Insights into the Fas ligand enigma. Nat Med 7: 271-274
30. Okada K, Komuta K, Hashimoto S, Matsuzaki S, Kanematsu T, Koji T (2000) Frequency of apoptosis of tumor-infiltrating lymphocytes induced by fas counterattack in human colorectal carcinoma and its correlation with prognosis. Clin Cancer Res 6: 3560-3564
31. Rabinowich H, Reichert TE, Kashii Y, Gastman BR, Bell MC, Whiteside TL (1998) Lymphocyte apoptosis induced by Fas ligand expressing ovarian carcinoma cells. Implications for altered expression of T cell receptor in tumor-associated lymphocytes. J Clin Invest 101: 2579-2588
32. Reimer T, Herrnring C, Koczan D, Richter D, Gerber B, Kabelitz D, Friese K, Thiesen HJ (2000) FasL:Fas ratio - a prognostic factor in breast carcinomas. Cancer Res 60: 822-828
33. Remmele W, Hildebrand U, Hienz HA, Klein PJ, Vierbuchen M, Behnken LJ, Heicke B, Scheidt E (1986) Comparative histological, histochemical, immunohistochemical and biochemical studies on oestrogen receptors, lectin receptors, and Barr bodies in human breast cancer. Virchows Arch A Pathol Anat Histopathol 409: 127-147
34. Reubi JC, Waser B, Vale W, Rivier J (2003) Expression of CRF1 and CRF2 receptors in human cancers. J Clin Endocrinol Metab 88: 3312-3320
35. Saas P, Walker PR, Hahne M, Quiquerez AL, Schnuriger V, Perrin G, French L, Van Meir EG, de Tribolet N, Tschopp J, Dietrich PY (1997) Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain? J Clin Invest 99: 1173-1178
36. Sato H, Nagashima Y, Chrousos GP, Ichihashi M, Funasak Y (2002) The expression of corticotropin-releasing hormone in melanoma. Pigment Cell Res 15: 98-103
37. Shibakita M, Tachibana M, Dhar DK, Kotoh T, Kinugasa S, Kubota H, Masunaga R, Nagasue N (1999) Prognostic significance of Fas and Fas ligand expressions in human esophageal cancer. Clin Cancer Res 5: 2464-2469
38. Suda T, Okazaki T, Naito Y, Yokota T, Arai N, Ozaki S, Nakao K, Nagata S (1995) Expression of the Fas ligand in cells of T cell lineage. J Immunol 154: 3806-3813
39. Suda T, Tomori N, Yajima F, Odagiri E, Demura H, Shizume K (1986) Characterization of immunoreactive corticotropin and corticotropin-releasing factor in human adrenal and ovarian tumours. Acta Endocrinol (Copenh) 111: 546-552
40. Tjuvajev J, Kolesnikov Y, Joshi R, Sherinski J, Koutcher L, Zhou Y, Matei C, Koutcher J, Kreek MJ, Blasberg R (1998) Anti-neoplastic properties of human corticotropin releasing factor: involvement of the nitric oxide pathway. In vivo 12: 1-10
41. van Haaften-Day C, Russell P, Davies S, King NJ, Tattersall MH (2003) Expression of Fas and FasL in human serous ovarian epithelial tumors. Hum Pathol 34: 74-79
42. Volm M, Koomagi R (2000) Relevance of proliferative and pro-apoptotic factors in non-small-cell lung cancer for patient survival. Br J Cancer 82: 1747-1754
43. Yakes FM, Wamil BD, Sun F, Yan HP, Carter CE, Hellerqvist CG (2000) CM101 treatment overrides tumor-induced immunoprivilege leading to apoptosis. Cancer Res 60: 5740-5746
44. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, Rubin SC, Coukos G (2003) Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348: 203-213
45. Zheng HC, Sun JM, Wei ZL, Yang XF, Zhang YC, Xin Y (2003) Expression of Fas ligand and caspase-3 contributes to formation of immune escape in gastric cancer. World J Gastroenterol 9: 1415-1420